abrdn plc Raises Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

abrdn plc raised its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 6.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 457,695 shares of the biotechnology company’s stock after buying an additional 26,597 shares during the period. abrdn plc owned about 0.48% of Sarepta Therapeutics worth $55,294,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Janus Henderson Group PLC boosted its holdings in Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after acquiring an additional 543,143 shares during the period. Wellington Management Group LLP grew its holdings in shares of Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after purchasing an additional 665,087 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after buying an additional 44,306 shares during the period. Jacobs Levy Equity Management Inc. raised its holdings in Sarepta Therapeutics by 9.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock valued at $94,148,000 after buying an additional 63,437 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in Sarepta Therapeutics during the 3rd quarter valued at $79,425,000. 86.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Robert W. Baird lowered their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Piper Sandler dropped their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Jefferies Financial Group began coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They issued a “buy” rating and a $165.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a report on Monday, January 27th. Finally, Guggenheim lifted their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $178.71.

Sarepta Therapeutics Stock Up 0.2 %

Shares of Sarepta Therapeutics stock opened at $114.08 on Wednesday. The company has a 50-day simple moving average of $122.45 and a two-hundred day simple moving average of $126.50. The stock has a market capitalization of $10.90 billion, a PE ratio of 91.26 and a beta of 0.75. Sarepta Therapeutics, Inc. has a 52-week low of $102.15 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.